Notably, an FDA-approved compound LC was identified and found to increase ZDHHC21 expression and decrease FASN expression as well as fatty acid synthesis, consequently suppressing DLBCL growth in vitro and in vivo. This evidence concerns the gene ZDHHC21 and diffuse large B-cell lymphoma.